MediWound Ltd.
MediWound Ltd. is a biopharmaceutical company focused on next-generation enzymatic therapies for non-surgical tissue repair. MediWound develops, manufactures, and commercializes products designed to address severe burns, chronic wounds, and other hard-to-heal tissue injuries. Its portfolio centers on biologic and protein-based treatments that selectively remove damaged tissue while preserving healthy tissue, supporting cleaner wound bed preparation and recovery care. The company serves hospitals, burn centers, and other healthcare providers involved in acute and specialized wound management. MediWound also works across tissue regeneration and related therapeutic areas, positioning itself within the broader wound care and regenerative medicine market. Headquartered in Yavne, Israel, MediWound emphasizes advanced, clinically focused solutions that aim to improve treatment workflows in modern wound care settings.
$11.85
-$0.36 (-2.95%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-149.06% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 16.1% YoY. Margins deteriorated 53.2pp alongside, both lines moving the wrong way.
ROIC dropped from -40.50% to -44.65%, capital efficiency is deteriorating. Negative free cash flow of -$22M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$12M
▼ -16.1% YoY
Net Income (TTM)
-$20M
▲ +21.0% YoY
Op. Margin
-267.86%
▼ -53.2pp YoY
ROIC
-44.65%
▼ -4.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$29M
▼ -8.7% YoY
Op. Cash Flow (TTM)
-$22M
▼ -18.3% YoY
Net Debt
-$45M
Net Cash Position
Cash & Equiv.
$53M
3Y CAGR: -13.8%
Continue Research
Is MediWound (MDWD) overvalued?
MediWound (MDWD)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, MediWound scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is MediWound a high-quality business?+
MediWound scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -267.9% operating margin and a -44.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is MediWound a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh MDWD's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.